Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers

Inclusion Criteria: * a confirmed gPV in MLH1 or MSH2 and without a prior history of MMR-D cancer. * a confirmed gPV in MSH6, whether or not they have a history of MMR-D cancer. MSH6 subjects with a history of MMR-D cancer have to be cancer-free for more than 1 year. * previous surgical treatment may include any resection up to and including hemicolectomy; subjects who have undergone (sub)total colectomy are excluded due to the substantially reduced risk of cancer occurrence. * aged between 35 and 75 for subjects with gPV in MLH1 and MSH2; and aged between 40 and 75 for subjects with gPV in MSH6. * Lynch syndrome subjects without clinical signs of disease. * Lynch syndrome subjects without prior treatment for LS-associated cancer, except for MSH6 subjects who are \>1 year disease-free and whose prior surgical treatment did not include subtotal colectomy. * Routine surveillance colonoscopy must be performed within 16 weeks prior to start of study, to exclude (pre)malignancy. * HLA-A02.01 genotype * Adequate hematologic, renal, and liver function as defined by laboratory values: WBC \>3.0\^109/l, lymphocytes \>0.8\^109/l, platelets \>100\^109/l, haemoglobin \>7,0 mmol/l (9.0 g/dl), estimated glomerular filtration rate \> 45 ml/min/1.73m2, AST/ALT \<3 x ULN, serum crea¬tinine \<150 µmol/l, serum bilirubin \<1.5 x ULN (exception: Gilbert's syndrome is permitted). * WHO performance status of 0 or 1 * No concomitant use of immunosuppressive drugs orally or intravenously. Topical a…